The world’s largest diabetic population resides in Asia Pacific due to which the demand for insulin is on a constant rise. Since the Asian countries reside majorly in the middle income group, diagnosis and treatment of diabetes does not reach to a large part of the population. Lack of awareness and affordability are the biggest hindrances to curbing diabetes in the region. Nevertheless, due to increasing level of education and consciousness in the Asian countries, people are gradually paying more attention to diabetes care and diagnosis.
Insulin, the basis of diabetes treatment has witnessed a surge in demand in the past decade. Factors such as growing diabetic population, increasing expenditure on healthcare both by the consumers and the government, expanding distribution network and high scope in developing economies such as China and India poses to be potential drivers for the insulin market in Asia Pacific. The regional market is growing on account of increasing volume sale of insulin in China and India, while Japan contributes the largest in terms of value.
“On account of preference and inclination towards analog insulin that offers higher level of effectiveness, the diabetic population in the Asia pacific is increasingly resorting to the same for treating diabetes”– according to the research report ‘Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin’ by Ken Research
The report provides detailed overview of the sales of insulin in countries including China, India and Japan and helps readers in identifying the ongoing trends in the key segments of the industry and anticipated growth in future depending upon changing industry dynamics in coming years. The report will aid industry consultants, insulin distributors, marketing companies and other stakeholders to align their market centric strategies according to ongoing and expected trends in future.